Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary

被引：0
|
作者：
Zoltán Vokó
László Nagyjánosi
Zoltán Kaló
机构：
[1] Eötvös Loránd University,Department of Health Policy & Health Economics, Institute of Economics, Faculty of Social Sciences
[2] Syreon Research Institute,undefined
[3] National Institute for Health Development,undefined
来源：
BMC Public Health | / 12卷
关键词：
Cervical cancer; Human papillomavirus; Vaccine; Cervarix; Hungary; Cost-effectiveness;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
下载
收藏
相关论文
共 50 条
  • [1] Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary
    Voko, Zoltan
    Nagyjanosi, Laszlo
    Kalo, Zoltan
    BMC PUBLIC HEALTH, 2012, 12
  • [2] COST-EFFECTIVENESS OF 2-DOSE AS04-ADJUVANTED HUMAN PAPILLOMAVIRUS 16/18 VACCINATION SCHEDULE IN SLOVAKIA
    Hlavinkova, L.
    Li, X.
    Van Kriekinge, G.
    Trnovec, P.
    VALUE IN HEALTH, 2014, 17 (07) : A634 - A634
  • [3] AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention
    Schwarz, Tino F.
    EXPERT REVIEW OF VACCINES, 2008, 7 (10) : 1465 - 1473
  • [4] Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, cervarixA®
    Schwarz, Tino F.
    ADVANCES IN THERAPY, 2009, 26 (11) : 983 - 998
  • [5] Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, cervarix®
    Tino F. Schwarz
    Advances in Therapy, 2009, 26 : 983 - 998
  • [6] Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule
    Julieta Germar, Maria
    Purugganan, Carrie
    Socorro Bernardino, Ma.
    Cuenca, Benjamin
    Chen, Y-Chen
    Li, Xiao
    Van Kriekinge, Georges
    Lee, I-Heng
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (05) : 1158 - 1166
  • [7] Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women
    Bhatla, Neerja
    Suri, Vanita
    Basu, Partha
    Shastri, Surendra
    Datta, Sanjoy K.
    Bi, Dan
    Descamps, Dominique J.
    Bock, Hans L.
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2010, 36 (01) : 123 - 132
  • [8] Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases
    Skinner, S. Rachel
    Apter, Dan
    De Carvalho, Newton
    Harper, Diane M.
    Konno, Ryo
    Paavonen, Jorma
    Romanowski, Barbara
    Roteli-Martins, Cecilia
    Burlet, Nansa
    Mihalyi, Attila
    Struyf, Frank
    EXPERT REVIEW OF VACCINES, 2016, 15 (03) : 367 - 387
  • [9] Vaccination with a Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Cervical Cancer Vaccine in Korean Girls Aged 10-14 Years
    Kim, Young-Jae
    Kim, Kyung-Tai
    Kim, Jae-Hoon
    Cha, Soon-Do
    Kim, Jae Weon
    Bae, Duk-Soo
    Nam, Joo-Hyun
    Ahn, Woong-Shick
    Choi, Ho-Sun
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2010, 25 (08) : 1197 - 1204
  • [10] Spotlight on AS04-Adjuvanted Human Papillomavirus (HPV) Types 16 and 18 Vaccine (Cervarix®)
    Kate McKeage
    Barbara Romanowski
    BioDrugs, 2011, 25 : 265 - 269
12345